Takeda Pharmaceutical Co Ltd: Q2 FY2021 Financial Summary
Business Context and Reporting Period
This Form 6-K summarizes Takeda Pharmaceutical Company Limited's Quarterly Securities Report for the six-month period ended September 30, 2021 (FY2021 H1). The report covers the second quarter of the 145th Business Term. Takeda is a global biopharmaceutical company focused on gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company reported no significant changes in its business scope, though it continued to integrate Shire plc and divest non-core assets.
Key Financial Metrics
| Metric (JPY Millions) | Six Months Ended Sep 30, 2020 | Six Months Ended Sep 30, 2021 | Change |
|---|---|---|---|
| Revenue | 1,590,785 | 1,794,423 | +12.8% |
| Operating Profit | 215,588 | 345,979 | +60.5% |
| Profit Before Tax | 125,561 | 284,425 | +126.5% |
| Net Profit (Attributable to Owners) | 86,548 | 183,648 | +112.2% |
| Basic EPS (JPY) | 55.45 | 117.08 | +111.1% |
| Operating Cash Flow | 392,011 | 400,011 | +2.0% |
| Cash and Equivalents (End of Period) | 630,868 | 607,881 | -3.6% |
| Total Debt (Bonds & Loans) | 4,635,371 | 4,231,359 | -8.7% |
Note: Debt figures represent carrying amounts of bonds and loans. Total equity increased to 5,324,361 million JPY.
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 12.8% year-over-year. This was significantly boosted by a one-time 133.0 billion JPY gain from the sale of a diabetes portfolio in Japan to Teijin Pharma Limited. Excluding this sale and foreign exchange impacts, underlying revenue growth was 6.8%.
- Profitability Surge: Net profit more than doubled (112.2% increase). This was driven by higher operating profit, a decrease in restructuring costs (down 26.0 billion JPY), and a significant one-time gain in the prior year (60.2 billion JPY revaluation gain on SHP647) that did not recur in the current period.
- Tax Impact: Income tax expenses rose 158.4% to 100.7 billion JPY, primarily due to a 63.7 billion JPY charge related to an Irish tax assessment on a break fee received from AbbVie in 2014.
- Debt Reduction: Total bonds and loans decreased by 404.0 billion JPY due to the redemption of senior notes and prepayment of loans, including a 2.0 billion USD prepayment of the Japan Bank for International Cooperation (JBIC) loan.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong performance in core therapeutic areas, particularly Gastroenterology (driven by ENTYVIO) and Plasma-Derived Therapies. Underlying Core Operating Profit grew 6.4% to 485.7 billion JPY, with a margin of 29.1%. The company continues to focus on R&D, with significant investments in oncology, rare diseases, and vaccines.
Risks and Contingencies:
- COVID-19: While the pandemic did not materially impact financial results, it caused fluctuations in demand for Neuroscience products (e.g., VYVANSE) due to reduced patient visits. Takeda is managing supply chains and clinical trials with caution.
- Litigation: Takeda settled patent infringement litigation regarding ADYNOVATE with Bayer; the settlement had no material impact as provisions were previously established. A tax dispute with Irish Revenue Commissioners regarding the AbbVie break fee resulted in a 480 million EUR provision.
- R&D Risks: The Phase 3 PANTHER study for pevonedistat (TAK-924) failed to meet its primary endpoint. Additionally, Phase 2 studies for TAK-994 (narcolepsy) were suspended early due to a safety signal.
Subsequent Events: On October 28, 2021, the Board resolved to repurchase up to 35 million shares (approx. 2.23% of outstanding shares) for up to 100 billion JPY to enhance capital efficiency. An interim dividend of 90 JPY per share was declared.
Key Facts for Investor Verification
- One-Time Revenue Impact: Verify the sustainability of revenue growth by excluding the 133.0 billion JPY one-time gain from the Japan diabetes portfolio sale.
- Tax Provision: Monitor the status of the Irish tax assessment appeal regarding the AbbVie break fee, which resulted in a significant tax charge.
- R&D Pipeline: Assess the impact of the failed PANTHER trial (pevonedistat) and the suspension of TAK-994 studies on future growth projections.
- Share Repurchase: Confirm the execution and timing of the newly authorized 100 billion JPY share buyback program.
- Debt Maturity: Review the schedule for the remaining JBIC loan prepayment (1.7 billion USD) due in December 2021, funded by a new bond issuance.